我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

氟伐他汀对充血性心力衰竭患者血清sICAM-1和sVCAM-1的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第3期
页码:
408-411
栏目:
临床研究
出版日期:
2010-04-06

文章信息/Info

Title:
Effects of fluvastatin on serum sICAM-1 and sVCAM-1 in patients with congestive heart failure
作者:
李争1; 马立庆2; 朱卉2; 黄喆2; 吴云涛2; 郑晓明2
华北煤炭医学院：1.附属中医医院心内科，河北 唐山 063000； 2.附属开滦有限责任公司医院心内科，河北 唐山 063000
Author(s):
LI Zheng1;  MA Li-qing2;  ZHU Hui2;  HUANG Zhe2;  WU Yun-tao2;  ZHENG Xiao-ming2
1.Department of Cardiology, Affiliated Hospital of Traditional Chinese Medicine, 2.Department of Cardiology, Affiliated Hospital of Kai Luan Limited Liability Company, North China Coal Medical University, Tangshan 063000, Hebei, China
关键词:
心力衰竭; 充血性; 氟伐他汀; 细胞间黏附分子-1; 血管细胞黏附分子-1
Keywords:
congestive heart failure;  fluvastatin;  intercellular adhesion molecule-1;  vascular cell adhesion molecule-1
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的: 探讨氟伐他汀短期治疗对充血性心力衰竭（CHF）患者血清中可溶性细胞间黏附分子-1（sICAM-1）、可溶性血管细胞黏附分子-1(sVCAM-1)和肿瘤坏死因子α(TNF-α)水平的影响。方法: 将97例CHF患者随机分为对照组（常规治疗组）和试药组（氟伐他汀组）。采用ELISA测定治疗前及治疗两周后血清中sICAM-1、sVCAM-1和TNF-α水平。 结果: 两种方法都可以明显降低血清sICAM-1、 sVCAM-1和TNF-α水平(P<0.05)；试药组血清TNF-α水平降低更为显著(P<0.05)，但血清sICAM-1和sVCAM-1降低水平与对照组无显著差别。结论: 在常规治疗基础上短期加用氟伐他汀治疗不能进一步降低CHF患者血清sICAM-1和sVCAM-1水平。
Abstract:
AIM: To observe the effects of short-term treatment of fluvastatin on serum soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and tumor necrosis factor-α (TNF-α) in patients with congestive heart failure (CHF). METHODS: Ninety seven patients with CHF were randomly divided into control group (conventional treatment group) and test drug group (fluvastatin group). Levels of serum sICAM-1, sVCAM-1 and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA) before treatment and after 2 weeks of treatment. RESULTS: Both methods can significantly reduce serum sICAM-1, sVCAM-1 and TNF-α level (P<0.05). TNF-α levels of test drug groups reduced more significantly (P<0.05), whereas decreased levels of serum sICAM-1 and sVCAM-1 had no significant difference compared with control group. CONCLUSION: On the basis of conventional treatment together with short-term fluvastatin treatment, no further reduction of the levels of sICAM-1 and sVCAM-1 were demonstrated.

参考文献/References

［1］ Valgimigli M, Curello S, Ceconi C, et al. Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart［J］. Cardiovasc Drugs Ther, 2001, 15(6):529-537.

［2］Klein RM, Breuer R, Mundhenke M, et al. Circulating adhesion molecules ( sICAM-1，sVCAM-1)in patients with suspected inflammatory heart muscle disease［J］. Z Kardiol, 1998, 87(2):84-93.

［3］Noutsias M, Pauschinger M, Schultheiss HP, et al. Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy［J］. Eur J Heart Fail, 2003, 5(4):469-479.

［4］ Sato T, Suzuki H, Shibata M, et al. Tumor-necrosis-factor-alpha-gene-deficient mice have improved cardiac function through reduction of intercellular adhesion molecule-1 in myocardial infarction［J］. Circ J, 2006, 70(12):1635-1642.

［5］ Ao L, Song Y, Fullerton DA, et al. The interaction between myocardial depressant factors in endotoxemic cardiac dysfunction： role of TNF-alpha in TLR4-mediated ICAM-1 expression［J］. Cytokine, 2007, 38(3):124-129.

［6］ Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure［J］. Am J Cardiol, 2004, 93(9):1124-1129.

［7］Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure［J］. Atherosclerosis, 2005, 178(2):359-363.

[8]Nawawi H, Osman NS, Annuar R, et al. Soluble intercellular adhesion molecule-1 and interleukin-6 level reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin［J］. Atherosclerosis, 2003, 169(2):283-291.

[9]庞文跃，姜立清，胡大一. 阿托伐他汀对人内皮细胞间黏附分子-1表达的影响［J］. 中国医药导刊， 2005， 7(4):295-297.

[10]Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function,and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level［J］. J Am Coll Cardiol, 2006, 47(2):338-341.

备注/Memo

备注/Memo:
收稿日期：2009-03-02.通讯作者：郑晓明，主任医师，主要从事心力衰竭的临床研究Email:tszhuhui@sina.com 作者简介：李争，主治医师，硕士Email:lizhengzhuhui@sina.com
更新日期/Last Update: 2010-04-09